Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Posted 36 Million Yuan Net Loss in First Half of 2022

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (上海复旦张江生物医药股份有限公司) (688505.SH) reported a net loss of 36 million yuan in the first half of 2022, reversing a net profit of 65.1 million yuan for the same period in the previous year.

Meanwhile, the company posted 271.3 million yuan in revenue, down 32% year-on-year.

At the end of the reporting period, it had 2.7 billion yuan in total assets and 579.3 million yuan in total liabilities, with a liability-to-asset ratio of 21.4%.